Phase 1 N=10 Effect of Allopregnanolone on Stress-induced Craving
Alcohol Use Disorder
Primary: Alcohol Urge Questionnaire (AUQ) Pre-script — 24.45; 21.51; 19.15; 26.29 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
Phase 1 N=21 Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
HIV-infection
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Phase 1 N=446 Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Locally Advanced and Metastatic Solid Tumors
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 1; 3; 6; 15 Participants
Phase 1 N=81 Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
RSV Infection
Primary: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade — 14; 7; 27; 11 Participants
Phase 1 N=6 A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Lungcancer
Primary: Recommended Dose in Milligrams Per Day for Binimetinib. — 30 mg
Phase 1 N=134 A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Solid Tumors · Metastatic Melanoma · Non-small Cell Lung Cancer (NSCLC)
Primary: Part A: Number of Participants With a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 Participants
Phase 1 N=24 PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Sample Time (AUC0-tlast) of Xevinapant (Debio 1143) — 9780; 10200 hours*nanogram per milliliter…
Phase 1 N=12 Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
Cervix Cancer · Cervix Intraepithelial Neoplasia Grade 3 · Cervix; Intraepithelial Neoplasia, Grade I
Primary: To Determine the Area Under the Plasma Concentration Versus Time Curve (AUC) of Dihydroartemisinin — 464.90 ng/mL-h
Phase 1 N=34 A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
Bipolar I Disorder
Primary: Number of Participants Who Experience One or More Adverse Events (AEs) — 9; 4; 1; 4 Participants
Phase 1 N=46 Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine
Enteric Fever
Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants
Phase 1 N=6 A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Six-minute Walk Distance — 32.3 Meters
Phase 1 N=26 Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
Wilson's Disease
Primary: Plasma Concentrations (AUC) of TETA 4HCL Following Administration of Two TETA 4HCL Tablet Formulations. — 12668.493; 10971.720; 13561.621; 11778.232 h*ng/mL
Phase 1 N=25 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Idiopathic Pulmonary Fibrosis
Primary: 1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs — 0; 0; 1; 0 Participants
Phase 1 N=16 Study to Evaluate the AIO-001 in Healthy Participants
Respiratory Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 6 Participants